Johnson & Johnson price target raised to $250 from $222 at TD Cowen

TD Cowen analyst Joshua Jennings raised the firm’s price target on Johnson & Johnson to $250 from $222 and keeps a Buy rating on the shares. Johnson & Johnson reported strong Q4 results with $24.6B in revenue, surpassing consensus, and its initial 2026 guidance is likely to lift Street revenue and EPS estimates, the analyst tells investors in a research note. Momentum in the Pharma and Devices franchises from 2H25 is expected to continue through 2026 and beyond, the firm says.